Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment.

Last updated: December 20, 2023
Sponsor: Universiteit Antwerpen
Overall Status: Active - Recruiting

Phase

N/A

Condition

Breast Cancer

Pain

Chronic Pain

Treatment

Biomarkers

Clinical Study ID

NCT05507034
1780
  • Ages 25-65
  • Female

Study Summary

Up to 40% of women experience chronic pain after treatment for breast cancer, and this pain is often very disabling. However, chronic pain after breast cancer remains under-recognised and undertreated. An effective and patient-tailored approach of (chronic) pain after breast cancer indeed requires a thorough knowledge and

evaluation of the pain. In daily clinical practice, however, guidelines for a comprehensive diagnosis of pain in cancer patients and survivors are lacking. Further research in this topic is crucial for an efficient, preventive as well as curative, approach of pain after breast cancer. Besides the high prevalence and the important impact of pain in this population, the breast cancer population is also an ideal population to study chronic pain and its natural time course in different stages, since most patients start pain-free, but almost half of them end up

with chronic pain. Therefore, this study aims to map biomarkers (both predictive, prognostic and diagnostic) for chronic pain after breast cancer treatment. We will study possible biopsychosocial biomarkers in

relation to (chronic) pain and monitor their temporal changes from the moment of diagnosis until 1 year after surgery. The potential biomarkers are situated within the medical imaging of the brain, measurements of pain sensitivity and psychological variables.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Unilateral breast cancer
  • Pain at enrollment <3/10 on average during the past week
  • First cancer diagnosis

Exclusion

Exclusion Criteria:

  • Pre-existing pain conditions
  • major pre-existing neurological disorders
  • No recurrent cancer or metastasis
  • No previous surgery in area

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: Biomarkers
Phase:
Study Start date:
October 04, 2022
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • University Hospital Antwerpen

    Wilrijk, Antwerpen 2610
    Belgium

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.